Search results
Showing 8051 to 8100 of 8235 results
NICE is making changes to simplify our offer to the life sciences industry.
NICE announces start of review of nusinersen Managed Access Agreement
NICE has today (29 October 2020) announced that it has begun the process to review data collected as part of the Managed Access Agreement (MAA) for nusinersen.
How we can offer a broader range of benefits for people, their families and carers
NICE has been part of a research project investigating how quality of life measures used to evaluate healthcare treatments such as drugs can be extended into areas of social care and public health.
In April 2021, the National Institute for Health Research (NIHR) launched a new rolling funding call for studies addressing NICE research recommendations.
NICE approves life-changing gene therapy for treating spinal muscular atrophy
A new one-off gene therapy for babies with the rare genetic disorder spinal muscular atrophy (SMA) is set to become the most expensive treatment ever approved by NICE.
Harriet Unsworth outlines her role in updating our evidence standards framework for digital health technologies. She also explains how you can share your views as part of our consultation.
How is NICE supporting digital health technology developers?
Richard Chivers, operations manager for NICE Scientific Advice, looks at how we’re supporting digital health technology developers and helping them with some of the challenges around evidence requirements and adoption within the NHS.
Self-harm is everyone's business, NICE says in new draft guideline
All professionals working across the health and social care system have a role to play in supporting people who self-harm and the issue should not just be seen as the responsibility of those with mental health expertise, NICE has said in a new draft guideline.
Using our guidance and resources in continuing professional development (CPD)
Registered social workers must demonstrate the use of evidence and research to inform their practice in order to meet professional standards. This is echoed in Social Work England’s continuing professional development (CPD) standards.
Increasing the capacity of our technology appraisals - the proportionate way
Jenniffer Prescott describes how we are trialling a proportionate approach to technology appraisals, which we expect will increase our capacity by 20% from 2023/24.
Pilar Pinilla-Dominguez reveals how NICE, through its international collaborations and partnerships, aims to contribute to improvements in health and care outcomes across the world, bringing learnings and benefits back to NICE, the NHS and the wider UK health and care system.
NICE calls for further research into the treatment of chronic lipoedema
NICE has today issued interventional procedures guidance on the use of liposuction for the treatment of chronic lipoedema.
Working at the forefront of neurodegenerative disease research
Claire Hawksworth reveals NICE’s role in a global partnership to better understand neurodegenerative conditions and speed up delivery of innovative treatments.
Dr Sam Roberts, chief executive of NICE, celebrates the NHS on its 75th anniversary. She discusses how NICE has supported the NHS with its recent achievements. She also highlights how NICE is evolving; through driving value-based healthcare to support the NHS as it adapts to meet current challenges.
To mark Time to Talk Day (February 2) we spoke with Catherine Ruane, who acted as a carer for her father and sister, who both lived with depression.
NICE guidance addresses the best approach to the diagnosis and management of ME/CFS
NICE has today (10 November 2020) published its draft guideline on the diagnosis and management of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).
Risdiplam not recommend for treating spinal muscular atrophy
NICE has today (2 June 2021) published draft guidance for which does not recommend risdiplam for treating the rare genetic disorder spinal muscular atrophy (SMA).
Over 500 people a year can access a new life extending lung cancer treatment
An innovative life-extending drug for treating mutation-positive locally advanced or metastatic non-small-cell lung cancer (NSCLC) in adults is being recommended by NICE as an option for use within the Cancer Drugs Fund.
NHS Talking Therapies for anxiety and depression services saw record referrals in 2023/24.
Benefits of new Alzheimer's treatment lecanemab are too small to justify the cost to the NHS
Our draft recommendation follows analysis of clinical trial evidence and reviewing the benefits of slowing disease progression, with the cost of treatment.
Two new treatment options for incurable blood cancer assessed
We’ve recommended 2 new treatments for multiple myeloma, an incurable blood cancer that affects bone marrow, in draft guidance issued for public consultation.
More than 20 pieces of draft and final guidance on a range of medicines and medical conditions were published during the pre-election period.
More than 700 people set to benefit from new treatment option for advanced lymphoma.
Children and young people set to benefit from new treatment for peanut allergy
Children and young people aged between 4 and 17 with a peanut allergy could benefit from Palforzia, a new treatment which can help build up their tolerance to peanut.
Colorectal cancer patients with rare mutations to benefit from life-extending treatment
NICE recommends pembrolizumab for colorectal cancer patients with rare mutations.
Shared decision making recommendations will ensure people are at the heart of healthcare
NICE’s new guideline on shared decision making will help transform people’s experiences of health and social care.
NICE recommends innovative technology for people with breast cancer
A magnetic marker liquid injected into people with invasive breast cancer will help surgeons discover if the cancer has spread.
Children with a rare, fatal, genetic disorder will be able to benefit from a new one-off treatment under new NICE guidance.
Healthier lifestyle can help to ease osteoarthritis symptoms says NICE
Exercise has an important role to play in helping people living with osteoarthritis NICE says in draft updated guidelines published today (29th April 2022).
Following the successful evaluation of Zio XT, developers of digital health technologies are encouraged to engage with NICE through one of several different routes.
People in England could benefit from new endometrial cancer treatment
Innovative new drug for treating endometrial cancer in adults recommended by NICE as an option for use within the Cancer Drugs Fund.
New guidance aims to achieve fairer outcomes for looked-after children and young people
Looked after children and young people should be considered ‘one of their own’ by carers, to help them to reach their full potential, new NICE draft guidelines say.
How my experience as a patient helped shape NICE guidelines for colorectal cancer
Following my surgery and treatment for colorectal cancer in 2014, I wanted to contribute to research in the cancer field and hopefully improve things for patients in the future.
New LSE master's degree in Evaluation of Health Care Interventions and Outcomes
NICE is collaborating with the London School of Economics and Political Science (LSE) to develop an executive master’s degree in health care decision-making.
NICE has recommended a new option for people with difficult-to-treat multiple myeloma
Around 5,700 cases of multiple myeloma are diagnosed each year in the UK. NICE has recommended a new option for people with difficult-to-treat multiple myeloma.
NICE’s methods and processes for evaluating new treatments for use in the NHS are appropriate for the new class of Alzheimer’s drugs but key issues need to be considered, a new report has found.
Learn more about the NICE and NHS England MedTech Pathway consultation
Home News Podcasts Learn more about the NICE and NHS England MedTech Pathway consultation Podcasts 03 June 2024 Listen About this episode
Learn more about NICE's new guideline on identifying and managing adrenal insufficiency
Home News Podcasts Learn more about NICE's new guideline on identifying and managing adrenal insufficiency Podcasts 29 August 2024 Listen
Find out about the role of NICE's independent advisory committees
Home News Podcasts Find out about the role of NICE's independent advisory committees Podcasts 31 October 2024 Listen About this episode We
Home News Podcasts Learn more about NICE's updated menopause guideline Podcasts 29 November 2024 Listen About this episode Our guests are
NICE recommends better targeting of antibiotics for suspected sepsis
Our guidance recommends better targeting of antibiotics to those at the highest risk of suspected sepsis to ensure the right people receive treatment.
NICE has approved mavacamten, the first treatment that specifically targets a heart condition called obstructive hypertrophic cardiomyopathy (HCM). It means around 7,000 people will now be able to access the treatment on the NHS.
New treatment for cardiovascular disease could benefit millions
Up to 2.1 million people with cardiovascular disease (CVD) could benefit from a new cholesterol target outlined in NICE guidance for the first time.
KardiaMobile recommended for people having antipsychotic medication
NICE publishes first draft guidance from its Early Value Assessment pilot project recommending smartphone-linked ECG device
Around 105,000 people with type 1 diabetes could benefit from NICE’s draft recommendation
Around 1,500 people aged 12 years and over with melanoma are set to benefit from pembrolizumab, a drug that reduces the chance of it returning.
NICE approves routine use of drug combination for advanced breast cancer
A life-extending drug combination for some people with advanced breast cancer will now be available for routine use in the NHS.
NICE welcomes Dr Michael Borowitz as new NICE non-executive director
New NICE non-executive director appointment approved by the Secretary of State for Health and Social Care
NICE conditionally recommends 5 promising technologies for Parkinson's disease
These promising technologies could help improve symptoms and quality of life for people with Parkinson’s disease.
Routine funding recommended for Duchenne muscular dystrophy gene therapy ataluren
NICE has today published final guidance which recommends ataluren (also called Translarna and made by PTC Therapeutics) for treating Duchenne muscular dystrophy (DMD) caused by a nonsense mutation.